$UNH

Conway Patrick Hugh sold $205K of UNH

Conway Patrick Hugh (Chief Executive Officer, Optum) sold 500 shares of UNITEDHEALTH GROUP INC (UNH) at $410.00 ($0.20M total) on 2026-08-05.

Original reporting
SEC EDGAR · Conway Patrick Hugh
Published Aug 7, 2026, 8:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 7, 2026, 8:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$UNH
Neutral
medium confidence
Mentioned
$UNH
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UNHNeutralLow
01

Why it matters

The only new information is the disclosed sale: 500 shares at $410 for about $205,000, with holdings after the transaction of 16,497 shares.

02

Market read

Traders may note insider selling as a sentiment datapoint, but there is no accompanying guidance, earnings, regulatory, or deal catalyst in the text.

03

What to watch

The article does not state whether the sale was part of a broader pattern, whether other insiders sold/bought, or whether there were concurrent compensation events that could explain the transaction.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-07, transaction dated 2026-08-05

Background

The filing is an SEC Form 4 insider transaction for UnitedHealth Group Inc, reported by Conway Patrick Hugh (CEO, Optum).

Company-level read

Ticker impact

$UNHNeutralMedium confidence
Context

UNH CEO of Optum, Conway Patrick Hugh, filed a Form 4 open-market sale of 500 shares at $410 on 2026-08-05.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven rather than fundamental.

Evidence & confidence

Form 4 insider sales can be routine and are not, by themselves, a new operating or guidance catalyst. The article provides transaction size, price, and post-sale holdings, but no accompanying company-specific news.

Market effects

Minimal; single-insider transaction in a large managed-care name does not change sector fundamentals.

None indicated.

None indicated.

Counterpoint

The sale may be tax or diversification related, especially since the filing does not provide context for motive and insider sales are often pre-planned even when not explicitly labeled as 10b5-1.

Key entities

  • UnitedHealth Group Inc

    Subject of the Form 4 insider transaction disclosure.

  • Conway Patrick Hugh

    Optum CEO and reporting insider who sold shares.

  • Optum

    Operating unit where the insider serves as CEO.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UNHHighAI 8/10

UnitedHealth Group (UNH) Raises 2026 Earnings Guidance, Boosting

UnitedHealth Group (UNH) reported Q3 2026 earnings of $4.69 per share, beating estimates by $0.55. The company raised its 2026 earnings guidance to at least $20.50 per share, up from the consensus of $19.87. Revenues were $112.7 billion, slightly down year-over-year but above projections. UNH offers a 2.29% dividend yield with a 52% payout ratio and a GF Score™ of 84, indicating strong fundamentals.

$UNHMed

Notable healthcare headlines for the week: J&J, UnitedHealth, and CVS in focus

UnitedHealth (UNH) raised 2026 earnings guidance after Q3 results beat estimates, with adjusted EPS at $4.69. Johnson & Johnson (JNJ) also raised full-year guidance. Roche (RHHBY) signed a $1.16B deal for an obesity drug. STERIS (STE) to acquire Xodus Medical for $2.1B. Iambic Therapeutics (IAM) debuted with a 10% rise. CVS (CVS) agreed to pay $315M over opioid prescription allegations.

$UNHMedAI 9/10

UnitedHealth's Q3 Margins Improve, But Membership Falls: Time to Buy?

UnitedHealth Group reported Q3 2026 adjusted earnings of $4.69 per share, beating estimates and raising its annual outlook to at least $20.50 per share. Revenues were $112.7 billion, with improved margins but declining membership. Optum's earnings rose despite revenue declines. Analysts revised earnings estimates higher, but challenges include medical utilization and Medicare Advantage ratings.

$UNHHighAI 9/10

Where Could UnitedHealth's Next Growth Come From?

UnitedHealth Group (UNH) raised its 2026 EPS outlook to $20.50, citing growth in Optum Health, its care division. Optum Health serves 20M patients, with 4M in fully accountable relationships, leaving room for expansion. It generated 22.8% of UNH's 2025 revenue but saw a 3.2% revenue decline. UNH's stock rose 16.0% YoY, lagging the S&P 500. Management targets 6-8% margins for Optum Health, a multi-year effort.

$UNHMedAI 8/10

Updated Sunlight Report Reveals 2,807 Entities Across UnitedHealth Group’s Corporate Empire

The Center for Health & Democracy updated its Sunlight Report, identifying 2,807 entities under UnitedHealth Group, including 376 new ones. The report highlights UnitedHealth's $3B acquisition of Alegeus Technologies and its vast healthcare network, while noting a slowdown in acquisition growth. The report has influenced national discussions and congressional investigations.

$UNHHighAI 9/10

What Happened With UnitedHealth Stock This Week?

UnitedHealth Group (UNH) shares rose 4.5% in two days, outperforming the S&P 500. Q3 2026 earnings beat estimates at $4.69 per share, while revenue matched expectations at $113 billion. The company raised its full-year 2026 earnings forecast to at least $19.50 per share, up from $18.70. Management attributed the results to strong execution across all business segments.